7-[((2S)-2-methyl-4-{[4-(trifluoromethyl)phenyl]sulfonyl}-1-piperazinyl)carbonyl]quinoline | 1342253-50-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-[((2S)-2-methyl-4-{[4-(trifluoromethyl)phenyl]sulfonyl}-1-piperazinyl)carbonyl]quinoline
• 英文别名: [(2S)-2-methyl-4-[4-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]-quinolin-7-ylmethanone
• CAS: 1342253-50-2
• 化学式: C₂₂H₂₀F₃N₃O₃S
• 分子量: 463.48
• InChiKey: VUILJMXNDIQVIA-HNNXBMFYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  32
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  79
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  (S)-(+)-2-甲基哌嗪 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 sodium hydroxide 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.42h， 生成 7-[((2S)-2-methyl-4-{[4-(trifluoromethyl)phenyl]sulfonyl}-1-piperazinyl)carbonyl]quinoline
  参考文献：
  名称：

  [EN] PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS
  [FR] DÉRIVÉS DE PIPÉRAZINE POUR BLOQUER DES CANAUX CALCIQUES CAV2.2

  摘要：

  本发明涉及新型哌嗪化合物；含有这些化合物的药物组合物；以及利用这些化合物在治疗中对治疗阻断Cav2.2钙通道有益的疾病和对治疗阻断Cav2.2和Cav3.2钙通道有益的疾病，例如治疗疼痛。

  公开号：

  WO2011086377A1

文献信息

• [EN] PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS<br/>[FR] DÉRIVÉS DE PIPÉRAZINE POUR BLOQUER DES CANAUX CALCIQUES CAV2.2
  申请人：CONVERGENCE PHARMACEUTICALS

  公开号：WO2011086377A1

  公开（公告）日：2011-07-21

  The present invention relates to novel piperazine compounds; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial and to treat diseases for which blocking the Cav2.2 and Cav3.2 calcium channels is beneficial, e.g. to treat pain.

  本发明涉及新型哌嗪化合物；含有这些化合物的药物组合物；以及利用这些化合物在治疗中对治疗阻断Cav2.2钙通道有益的疾病和对治疗阻断Cav2.2和Cav3.2钙通道有益的疾病，例如治疗疼痛。
• Piperazine derivatives for blocking Cav2.2 calcium channels
  申请人：Heer Jag Paul

  公开号：US08697703B2

  公开（公告）日：2014-04-15

  The present invention relates to novel piperazine compounds; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial and to treat diseases for which blocking the Cav2.2 and Cav3.2 calcium channels is beneficial, e.g. to treat pain.

  本发明涉及新型哌嗪化合物；含有该化合物的制药组合物；以及将该化合物用于治疗通过阻断Cav2.2钙通道有益的疾病，并用于治疗通过阻断Cav2.2和Cav3.2钙通道有益的疾病，例如治疗疼痛。
• METHODS OF TREATING HYPERSENSITIVE COUGH OR ITCHING USING ION CHANNEL INHIBITORY COMPOUNDS
  申请人：AFASCI, Inc.

  公开号：US20200069665A1

  公开（公告）日：2020-03-05

  The present invention is directed towards new chemical entities which primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity, particularly involved in hypersensitive cough or itching.
• US8697703B2
  申请人：——

  公开号：US8697703B2

  公开（公告）日：2014-04-15
• PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS
  申请人：Heer Jag Paul

  公开号：US20130072499A1

  公开（公告）日：2013-03-21

  The present invention relates to novel piperazine compounds; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Ca v 2.2 calcium channels is beneficial and to treat diseases for which blocking the Ca v 2.2 and Ca v 3.2 calcium channels is beneficial, e.g. to treat pain.

  本发明涉及新型哌嗪化合物；含有这些化合物的药物组合物；以及利用这些化合物在治疗中治疗阻断Ca v 2.2钙通道有益的疾病，以及治疗阻断Ca v 2.2和Ca v 3.2钙通道有益的疾病，例如治疗疼痛。